Solid Biosciences Future Growth
Future criteria checks 0/6
Solid Biosciences is forecast to grow earnings and revenue by 2.9% and 66.6% per annum respectively while EPS is expected to grow by 11.3% per annum.
Key information
2.9%
Earnings growth rate
11.3%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 66.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 08 Jan 2025 |
Recent future growth updates
Recent updates
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?
Nov 16
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Jul 26Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 9 | -183 | -179 | -160 | 5 |
| 12/31/2026 | N/A | -167 | -166 | -155 | 8 |
| 12/31/2025 | N/A | -139 | -141 | -120 | 11 |
| 12/31/2024 | N/A | -116 | -96 | -89 | 11 |
| 9/30/2024 | N/A | -102 | -92 | -91 | N/A |
| 6/30/2024 | N/A | -91 | -86 | -85 | N/A |
| 3/31/2024 | N/A | -90 | -93 | -91 | N/A |
| 12/31/2023 | N/A | -96 | -96 | -94 | N/A |
| 9/30/2023 | N/A | -91 | -110 | -108 | N/A |
| 6/30/2023 | N/A | -90 | -113 | -110 | N/A |
| 3/31/2023 | 6 | -91 | -102 | -99 | N/A |
| 12/31/2022 | 8 | -86 | -101 | -98 | N/A |
| 9/30/2022 | 11 | -89 | -87 | -84 | N/A |
| 6/30/2022 | 15 | -87 | -85 | -82 | N/A |
| 3/31/2022 | 12 | -81 | -85 | -84 | N/A |
| 12/31/2021 | 14 | -72 | -79 | -78 | N/A |
| 9/30/2021 | 10 | -75 | -56 | -56 | N/A |
| 6/30/2021 | 7 | -78 | -53 | -53 | N/A |
| 3/31/2021 | 3 | -78 | -49 | -49 | N/A |
| 12/31/2020 | N/A | -88 | -57 | -57 | N/A |
| 9/30/2020 | N/A | -99 | -81 | -79 | N/A |
| 6/30/2020 | N/A | -107 | -85 | -83 | N/A |
| 3/31/2020 | N/A | -114 | -99 | -96 | N/A |
| 12/31/2019 | N/A | -117 | -97 | -93 | N/A |
| 9/30/2019 | N/A | -107 | -98 | -93 | N/A |
| 6/30/2019 | N/A | -97 | -96 | -89 | N/A |
| 3/31/2019 | N/A | -89 | -88 | -79 | N/A |
| 12/31/2018 | N/A | -75 | -78 | -70 | N/A |
| 9/30/2018 | N/A | -67 | -69 | -63 | N/A |
| 6/30/2018 | N/A | -62 | N/A | -57 | N/A |
| 3/31/2018 | N/A | -55 | N/A | -50 | N/A |
| 12/31/2017 | N/A | -39 | N/A | -43 | N/A |
| 9/30/2017 | N/A | -29 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -17 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLDB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLDB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLDB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLDB is forecast to have no revenue next year.
High Growth Revenue: SLDB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLDB's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 15:02 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solid Biosciences Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Timothy Chiang | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |